Publications by authors named "Curdin Conrad"

Claim this Profile
N
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.
Franz J Legat, Shawn G Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Curdin Conrad

J Eur Acad Dermatol Venereol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
Joseph F Merola, Richard B Warren, Diamant Thaçi, Kenneth B Gordon, Emi Nishida, Curdin Conrad

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitization Patterns to Cyanoacrylate-Based Surgical Glues.
Lucrezia Bianchetti, Anna Walker, Ophelie Marchal, Laura Bruschi, Héloïse Wüthrich, Curdin Conrad

Contact Dermatitis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review.
Simone Lisa Böll, Seyed Morteza Seyed Jafari, Curdin Conrad, Christoph Schlapbach

Int J Mol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains.
Fanny Saidoune, Danyel Lee, Jeremy Di Domizio, Corentin Le Floc'h, Raphael Jenelten, Curdin Conrad

J Exp Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life.
Matthias Augustin, Jonathan Barker, Curdin Conrad, Denis Jullien, Jose-Manuel Carrascosa

Dermatol Ther (Heidelb)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis.
Sara E Cerminara, Ivana Cvijetic, Stephanie Huber, Simon Müller, Lisa Kostner, Curdin Conrad

J Eur Acad Dermatol Venereol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis.
Roberto Lande, Anna Mennella, Raffaella Palazzo, Rebecca Favaro, Paola Facheris, Curdin Conrad

Front Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis.
Claire Fossati, Emmanuella Guenova, Curdin Conrad, Michel Gilliet, Teofila Seremet

J Eur Acad Dermatol Venereol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT).
Ramtin Lichtenberger, Lara Valeska Maul, Ion Birkenmaier, Iker Oyanguren, Melike Ak, Curdin Conrad

Acta Derm Venereol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A European Roundtable "Addressing Under-Prioritized Skin Diseases: Policy Responses to High-Burden Conditions".
Yalchin Mammadov, Jennifer Austin, Tammi Shipowick, Karin Veldman, Sabine Eming, Curdin Conrad

J Invest Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases.
Teofila Seremet, Jeremy Di Domizio, Antoine Girardin, Ahmad Yatim, Raphael Jenelten, Curdin Conrad

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Andrea Chiricozzi, Giulia Coscarella, Luis Puig, Ron Vender, Jensen Yeung, Curdin Conrad

J Eur Acad Dermatol Venereol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
Niccolò Gori, Elena Ippoliti, Silvia Mariel Ferrucci, Anna Balato, Michela Ortoncelli, Curdin Conrad

J Eur Acad Dermatol Venereol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of initiating biologics in the treatment of psoriasis.
Emilia Linnemann, Mia-Louise Nielsen, Lara Valeska Maul, Clara Richter, Isabella Dommann, Curdin Conrad

Int J Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis.
Andrew Blauvelt, Curdin Conrad, Megan H Noe

JAMA Dermatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
Luis Puig, Antonio Costanzo, Elke M G J de Jong, Tiago Torres, Richard B Warren, Curdin Conrad

Dermatol Ther (Heidelb)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting IL-1 controls refractory pityriasis rubra pilaris.
Eloi Schmauch, Yannik Severin, Xianying Xing, Aaron Mangold, Curdin Conrad

Sci Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26.
Alessia Baldo, Jeremy Di Domizio, Ahmad Yatim, Sophie Vandenberghe-Dürr, Raphael Jenelten, Curdin Conrad

J Exp Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT).
Fabio Verardi, Lara Valeska Maul, Kim Borsky, Simona Steinmann, Nina Rosset, Curdin Conrad

J Eur Acad Dermatol Venereol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study.
Mia-Louise Nielsen, Troels C Petersen, Lara Valeska Maul, Jacob P Thyssen, Simon F Thomsen, Curdin Conrad

J Psoriasis Psoriatic Arthritis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze

Dermatol Ther (Heidelb)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment of childhood psoriasis: present and future].
Francesco Messina, Curdin Conrad, Marie-Anne Morren

Rev Med Suisse· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis.
Curdin Conrad, Christoph Schlapbach

J Allergy Clin Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Shawn G Kwatra, Gil Yosipovitch, Franz J Legat, Adam Reich, Carle Paul, Curdin Conrad

N Engl J Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis